Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - azathioprine, quantity: 50 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; mannitol; maize starch; povidone; croscarmellose sodium; sodium stearylfumarate; hypromellose; macrogol 400 - azathioprine is used as an immunosuppressant/antimetabolite either alone or, more commonly, in combination with the other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effect may be evident only after weeks or months and can include a steroid sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. azathioprine, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants. azathioprine, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering from the following: severe rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis/polymyositis, autoimmune chronic active hepatitis, pemphigus vulgaris, polyarteritis nodosa, autoimmune haemolytic anaemia and chronic refractory idiopathic thrombocytopenic purpura.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - mesalazine, quantity: 250 mg - tablet, enteric coated - excipient ingredients: microcrystalline cellulose; povidone; sodium carbonate; purified talc; titanium dioxide; iron oxide red; colloidal anhydrous silica; calcium stearate; glycine; iron oxide yellow; methacrylic acid copolymer; macrogol 6000; triethyl citrate - indications as at 12 september 1990: treatment of acute inflammatory large bowel disease. maintenance therapy of crohns colitis and ulcerative colitis in patients sensitive to sulfasalazine.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; hyprolose; purified talc; titanium dioxide; hypromellose; iron oxide red; iron oxide black; macrogol 400; indigo carmine aluminium lake - prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. prophylaxis of organ rejection in paediatric patients (with a body surface area > 1.5 m2) receiving allogeneic renal transplants.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; hyprolose; purified talc; titanium dioxide; hypromellose; iron oxide red; iron oxide black; macrogol 400; indigo carmine aluminium lake - prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. prophylaxis of organ rejection in paediatric patients (with a body surface area > 1.5 m2) receiving allogeneic renal transplants.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; hyprolose; purified talc; titanium dioxide; hypromellose; iron oxide red; iron oxide black; macrogol 400; indigo carmine aluminium lake - prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. prophylaxis of organ rejection in paediatric patients (with a body surface area > 1.5 m2) receiving allogeneic renal transplants.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; hyprolose; povidone; purified talc; magnesium stearate; titanium dioxide; hypromellose; iron oxide red; iron oxide black; macrogol 400; indigo carmine aluminium lake - prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. prophylaxis of organ rejection in paediatric patients (with a body surface area > 1.5 m2) receiving allogeneic renal transplants.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - febuxostat, quantity: 80 mg - tablet - excipient ingredients: microcrystalline cellulose; hyprolose; croscarmellose sodium; magnesium stearate; silicon dioxide; lactose monohydrate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - treatment of chronic symptomatic hyperuricaemia in conditions where urate deposition has already occurred (gouty arthritis and/or tophus formation) in adults with gout.

Spojené státy - angličtina - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - azathioprine (unii: mrk240iy2l) (azathioprine - unii:mrk240iy2l) - azathioprine 50 mg - azathioprine tablets usp are indicated as an adjunct for the prevention of rejection in renal homotransplantation. it is also indicated for the management of active rheumatoid arthritis to reduce signs and symptoms. azathioprine tablets usp are indicated as an adjunct for the prevention of rejection in renal homotransplantation. experience with over 16,000 transplants shows a 5-year patient survival of 35% to 55%, but this is dependent on donor, match for hla antigens, anti-donor or anti-b-cell alloantigen antibody, and other variables. the effect of azathioprine on these variables has not been tested in controlled trials. azathioprine tablets usp are indicated for the treatment of active rheumatoid arthritis (ra) to reduce signs and symptoms. aspirin, non-steroidal anti-inflammatory drugs and/or low dose glucocorticoids may be continued during treatment with azathioprine. the combined use of azathioprine with disease modifying anti-rheumatic drugs (dmards) has not been studied for either added benefit or une

Spojené státy - angličtina - NLM (National Library of Medicine)

rebel distributors corp.. - azathioprine (unii: mrk240iy2l) (azathioprine - unii:mrk240iy2l) - azathioprine 50 mg - azathioprine tablets are indicated as an adjunct for the prevention of rejection in renal homotransplantation. it is also indicated for the management of active rheumatoid arthritis to reduce signs and symptoms. azathioprine tablets are indicated as an adjunct for the prevention of rejection in renal homotransplantation. experience with over 16,000 transplants shows a 5-year patient survival of 35% to 55%, but this is dependent on donor, match for hla antigens, anti-donor or anti-b-cell alloantigen antibody, and other variables. the effect of azathioprine tablets on these variables has not been tested in controlled trials. azathioprine tablets are indicated for the treatment of active rheumatoid arthritis (ra) to reduce signs and symptoms. aspirin, non-steroidal anti-inflammatory drugs and/or low dose glucocorticoids may be continued during treatment with azathioprine tablets. the combined use of azathioprine tablets with disease modifying anti-rheumatic drugs (dmards) has not been studied for either added be

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sirolimus, quantity: 0.5 mg - tablet, sugar coated - excipient ingredients: dl-alpha-tocopherol; iron oxide yellow; macrogol 8000; carnauba wax; iron oxide red; microcrystalline cellulose; purified talc; iron oxide black; povidone; magnesium stearate; macrogol 20000; shellac; sucrose; calcium sulfate; glyceryl monooleate; titanium dioxide; poloxamer; lactose monohydrate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; simethicone; ethanol; sulfuric acid - rapamune is indicated for the prophylaxis of organ rejection in patients at mild to moderate immunological risk receiving renal transplants. therapeutic drug monitoring of sirolimus is required.